About Us

Welcome to Thrombosis Adviser... your global thrombosis hub

This section introduces our vision for Thrombosis Adviser and provides an overview of all the contributors and their roles

In this section:

Your thrombosis hub

The field of thrombosis is exciting and fast moving, but keeping up-to-date with the vast number of studies and technological advances across all aspects of thrombosis is a challenge for us all
With Thrombosis Adviser, we aim to improve the understanding and management of thromboembolic disorders by becoming a global thrombosis hub that provides trustworthy, balanced educational materials for all our readers
You can access key information quickly through short, focussed articles and dynamic content, such as video clips and animations, or visit the ‘Knowledge Base’ for more detailed therapy area content
Information can be viewed and shared easily, whichever platform you favour
We hope that in this ever-changing environment you find Thrombosis Adviser informative and inspiring. Share you experiences with colleagues and friends using the social icons below

Meet the Steering Committee

Emeritus Professor Sylvia Haas, MD, PhD

Emeritus Professor of Medicine and former Director of the Haemostasis and Thrombosis Research Group at Klinikum re. der Isar, Technical University of Munich, Germany.
Scientific focus: experimental and clinical thrombosis research, development of new antithrombotic therapies, laboratory measurement and monitoring of anticoagulants, prevention and treatment of venous and arterial thromboembolism
Member of several international professional societies and of several editorial boards for peer-reviewed journals
In charge of a variety of integrated teaching programmes

Gregory Y H Lip

Liverpool Centre for Cardiovascular Science at the University of Liverpool and Liverpool Heart & Chest Hospital, United Kingdom

Professor Lip, MD, is Price-Evans Chair of Cardiovascular Medicine, at the University of Liverpool, UK – and Director of the Liverpool Centre for Cardiovascular Science at the University of Liverpool and Liverpool Heart & Chest Hospital. He is also Distinguished Professor at Aalborg University, Denmark; Adjunct Professor at Yonsei University and Seoul National University, Seoul, Korea. He also holds Visiting or Honorary Professorships in various other Universities in UK, Serbia (Belgrade), China (Beijing, Nanjing, Guangzhou), Thailand (Chiangmai) and Taiwan (Taipei).Half of his time is spent as a clinical cardiologist, including outpatient clinics (leading atrial fibrillation and hypertension specialist services) and acute cardiology.

Professor Lip has had a major interest into the epidemiology of atrial fibrillation (AF), as well as the pathophysiology of thromboembolism in this arrhythmia. Furthermore, he has been researching stroke and bleeding risk factors, and improvements in clinical risk stratification. The CHA2DS2-VASc and HAS-BLED scores - for assessing stroke and bleeding risk, respectively – were first proposed and independently validated following his research, and are now incorporated into international guidelines. In 2014, Professor Lip was ranked by Expertscape as the world's leading expert in the understanding and treatment of AF [http://bit.ly/2apB1Dt], a position still maintained in 2020 (https://bit.ly/3eP3qR4).

Professor Lip was on the writing committee for various international guidelines, including the American College of Chest Physicians (ACCP) Antithrombotic Therapy Guidelines for Atrial Fibrillation, as well as various guidelines and/or position statements from the European Society of Cardiology (ESC) or EHRA. He was recently Chair of the new 2018 ACCP Guidelines on antithrombotic therapy for AF.

Professor Lip has acted as senior/section editor for major international textbooks and at senior editorial level for major international journals, including Thrombosis & Haemostasis (Editor-in-Chief, Clinical Studies); Europace (Associate Editor); and Circulation (Guest Editor).

Professor Alexander GG Turpie, MD

Emeritus Professor of Medicine at McMaster University, Hamilton, Ontario, Canada
Scientific focus: new antithrombotic drugs for the management of venous and arterial thrombosis and anticoagulant therapy in patients with prosthetic heart valves
Served on numerous professional and university-related committees and is a frequent lecturer at professional meetings worldwide
Authored more than 700 published articles, abstracts, book chapters and books; reviewer for many journals including Annals of Internal Medicine, Circulation, The Lancet and The New England Journal of Medicine; and serves on the editorial boards of Vascular Medicine Review and HeartDrug

Rt Hon Professor the Lord Kakkar PC PhD FRCS FMedSci

The Rt. Hon. Professor the Lord Kakkar PC is Professor of Surgery, University College London, and Director of the Thrombosis Research Institute. He is Chairman of UCLPartners Academic Health Science Partnership, the King’s Fund and UK Biobank.

Lord Kakkar completed his medical degree at King’s College Hospital Medical School and received his PhD from Imperial College London. He has been a fellow of the Royal College of Surgeons since 1992. His research interests include the prevention and treatment of venous and arterial thromboembolic disease and cancer associated thrombosis.

Lord Kakkar was created a Life Peer in 2010 and sits on the cross benches of the House of Lords. He is Chairman of the Judicial Appointments Commission and was appointed a member of Her Majesty’s Most Honourable Privy Council in 2014.

Up-to-date content you can rely on

The content for Thrombosis Adviser is assessed on an ongoing basis to provide up-to-date, relevant information

A daily literature review is undertaken using validated scientific search criteria and the PubMed database to search for new publications under each key topic relevant to the website
The results are reviewed for relevance based on pre-defined inclusion criteria, as agreed by the Steering Committee
Guideline recommendations from internationally recognized bodies and data from randomized controlled clinical trials are prioritized when selecting new topics and updating existing content for the website

What else do you need to know?

The role of the sponsor (Bayer AG)

The sponsor provides financial support for the website, and reviews content to ensure accuracy of information in compliance with established pharmaceutical codes of practice

Where to next?

Latest in Thrombosis